Edition:
United States

Thermo Fisher Scientific Inc (TMO.N)

TMO.N on New York Stock Exchange

168.01USD
26 Apr 2017
Change (% chg)

$9.20 (+5.79%)
Prev Close
$158.81
Open
$162.00
Day's High
$168.12
Day's Low
$160.99
Volume
955,868
Avg. Vol
430,970
52-wk High
$168.12
52-wk Low
$139.07

Latest Key Developments (Source: Significant Developments)

Thermo Fisher Scientific posts Q1 adj earnings of $2.08/share
Wednesday, 26 Apr 2017 06:00am EDT 

April 26 (Reuters) - Thermo Fisher Scientific Inc :Q1 adjusted earnings per share of $2.08.Q1 revenue grew 11 percent to $4.77 billion.Q1 GAAP earnings per share $1.40.Says raising 2017 revenue guidance to range of $19.51 billion to $19.71 billion versus original guidance of $19.38 billion to $19.62 billion.Says raising 2017 adjusted EPS guidance to range of $9.12 to $9.28 versus the $9.06 to $9.24 previously communicated.In the first quarter of 2017, life sciences solutions segment revenue grew 12 percent to $1.36 billion.Q1 earnings per share view $2.02, revenue view $4.68 billion -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $9.17, revenue view $19.53 billion -- Thomson Reuters I/B/E/S.  Full Article

SpeeDx, Thermo Fisher announce partnership for FDA clearance of Molecular Diagnostic
Monday, 24 Apr 2017 08:00am EDT 

April 24 (Reuters) - SpeeDx::SpeeDx and Thermo Fisher Scientific announce strategic partnership for FDA clearance of Molecular Diagnostic.SpeeDx- Signed agreement with Thermo Fisher in support of SpeeDx's plan to submit its ResistancePlus MG test for clearance by U.S. FDA.  Full Article

Thermo Fisher Scientific transferred plastics for cell culture and vaccines to life sciences solutions segment
Monday, 17 Apr 2017 08:01am EDT 

April 17 (Reuters) - Thermo Fisher Scientific Inc :Thermo Fisher Scientific - Effective Jan 1, co transferred its plastics for cell culture and vaccines/biologics to life sciences solutions segment.Thermo Fisher - Also transferred sample preparation and analysis, production chemicals product lines to life sciences solutions segment - sec filing.Thermo Fisher Scientific - Effective Jan 1, transferred biochemical product line from life sciences solutions segment to laboratory products & services.Thermo Fisher Scientific Inc - Effective January 1, 2017, co transferred certain product lines to further align its products and commercial teams.  Full Article

Thermo fisher scientific CEO Marc Casper's total 2016 compensation was $17.8 mln
Tuesday, 4 Apr 2017 08:32am EDT 

Thermo Fisher Scientific Inc :Says ceo Marc Casper's total 2016 compensation was $17.8 million versus $16.3 million in 2015 - SEC filing.  Full Article

Thermo Fisher Scientific and Cell And Gene Therapy Catapult collaborate
Tuesday, 21 Mar 2017 08:27am EDT 

Thermo Fisher Scientific Inc :Thermo Fisher Scientific Inc - co and Cell And Gene Therapy Catapult collaborate to optimise advanced therapy supply chain.  Full Article

Thermo Fisher issues 500 mln euro of certain senior notes due 2027
Thursday, 16 Mar 2017 06:58am EDT 

Thermo Fisher Scientific Inc : On March 16, 2017, issued EUR 500 million aggregate principal amount of 1.450 pct senior notes due 2027 . Notes will mature on March 16, 2027 - SEC filing .Interest on notes will accrue at rate of 1.450 percent per annum.  Full Article

Thermo Fisher Scientific prices offering of Euro-denominated senior notes
Tuesday, 7 Mar 2017 05:05pm EST 

Thermo Fisher Scientific Inc : Thermo Fisher Scientific prices offering of euro-denominated senior notes . Thermo Fisher Scientific - priced offering of eur500 million of 1.450% senior notes due 2027 at an issue price of 98.824% of principal amount .Notes will pay interest on an annual basis.  Full Article

Thermo Fisher Scientific elects new director to board
Wednesday, 1 Mar 2017 09:00am EST 

Thermo Fisher Scientific Inc : Thermo Fisher Scientific elects new director to board . Thermo Fisher Scientific Inc says has elected Dion Weisler to its board of directors .Thermo Fisher Scientific Inc says Weisler's appointment brings total number of Thermo Fisher board members to 12.  Full Article

Achaogen Inc says strategic milestone achieved in TDM Assay development
Wednesday, 22 Feb 2017 04:01pm EST 

Achaogen Inc : Achaogen Inc says strategic milestone achieved in TDM Assay development . Achaogen Inc says Thermo Fisher Scientific to develop and then commercialize its assay for measuring concentration of plazomicin . Achaogen Inc says achieved a strategic milestone in their ongoing efforts to develop an assay enabling therapeutic drug management of plazomicin . Plans to submit a new drug application (NDA) for plazomicin to Food and Drug Administration (FDA) in second half of 2017 .Says also plans to submit a marketing authorization application (MAA) to European Medicines Agency (EMA) in 2018.  Full Article

Asuragen enters into collaboration deal with Thermo Fisher
Monday, 20 Feb 2017 09:00am EST 

:Asuragen Inc - Entered collaboration deal with Thermo Fisher scientific for development, commercialization of capillary electrophoresis-based in vitro diagnostics.  Full Article

More From Around the Web

Thermo Fisher tops profit estimate, ups forecast

Thermo Fisher Scientific Inc on Wednesday reported higher-than-expected first quarter profit on increased sales in all of its divisions and raised its full-year earnings and revenue forecasts.